Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-DC-CTL Cell Therapy in Advanced Non-small Cell Lung Cancer
ChiCTR-IIR-16008727Phase 3Recruiting
- Sponsor
- Shanghai East Hospital
- Start
- Dec 2015
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics, RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of mRNA-DC-CTL cells in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Shanghai East Hospital. Primary endpoints: Adverse events, Progression-free survival and 3 more. Started Dec 2015; status: recruiting.
02
Drugs
mRNA-DC-CTL cells
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR-IIR-16008727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IIR-16008727.